Abstract
Thirty patients in E. N. T. Clinic of Kyoto University, complaining of hyperrhinorrhea, nasal obstruction, hyposmia and other nasopharyngeal symptoms were treated with peroral administration of EMPYNASE capsules, a kind of anti-inflammatory proteolytic enzyme. The marked effect for subjective complaints was recognized in 23% of the cases, good effect in 40%, poor result in 37% and no apparent side effect was observed in the all cases.
The authors concluded that EMPYNASE was available for a pharmacotherapy of chronic rhinitis and paranasal sinusitis.
